EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Assessing the Reduction of Recurrent Admissions Using OM ‐85 for the Treatment of Preschool Wheeze ( ARROW ): Protocol for a Multi‐Centre, Randomised, Double‐Blind, Placebo‐Controlled Trial

Jessica C Costa-Pinto iD, Marisa van Arragon, Katherine J Lee iD, Lisa Gold iD, Peter D Sly iD, Cameron C Grant, Sarah McNab, Peter Vuillermin iD, Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) Investigator Group

Journal of Paediatrics and Child Health · 2026-07 · 62 (7) · 1244-1254

DOI: 10.1111/jpc.70434 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Paediatrics and Child Health, online erschienen am 15.06.2026. Verfasst von Jessica C Costa-Pinto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Deakin University, Geelong, Victoria, Australia. Hauptthemen laut MEDLINE: Cell Extracts, Patient Readmission, Respiratory Sounds. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Starship Foundation, Cure Kids.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Acute wheezing illnesses are among the most common reasons preschool‐aged children are admitted to hospital. Readmission rates are high, and novel preventive strategies are required. OM‐85 is an orally administered bacterial lysate that stimulates anti‐viral immune responses and reduces excessive airway inflammation associated with wheezing episodes. The aim of the Assessing the Reduction of Recurrent admissions using OM‐85 for the treatment of preschool Wheeze (ARROW) trial is to determine the efficacy of OM‐85 in preventing hospital readmissions in children admitted to hospital with preschool wheeze. The primary outcome is hospital admission due to an acute wheezing illness during the 12‐month treatment period. Secondary outcomes include the frequency and duration of wheeze episodes and the cost‐effectiveness of the intervention.

Methods

ARROW is a decentralised, Phase 3 randomised, double‐blind, placebo‐controlled trial. We aim to recruit and follow‐up 870 children aged 1 to < 6 years. Participants are randomised to 3.5 mg of OM‐85 or placebo daily for the first 10 days of every month, for 12 months. Health professionals from over 40 hospitals participating in the Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) invite families to the ARROW trial. The ARROW central team organises enrolment, randomisation, medication distribution, and follow‐up, conducting these activities entirely remotely in Australia and both remotely and in‐person in New Zealand. Ethics and Dissemination ARROW received ethics approval from The Royal Children's Hospital Human Research Ethics Committee in Australia and the Health and Disability Ethics Committee in New Zealand. Findings will be published in peer‐reviewed international journals.

Trial registration

ANZCTR: ACTRN12620001370998 (Registered on 21 December 2020).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell ExtractsPatient ReadmissionRespiratory SoundsChild, PreschoolFemaleHumansInfantMaleAustraliaBacterial LysatesDouble-Blind MethodHospitalizationNew ZealandTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

OM‐85Paediatricsimmunomodulatorpreschool asthmapreschool wheezerandomised controlled trial

Substanzen

Bacterial LysatesBroncho-VaxomCell Extracts

Autor:innen und Institutionen

  • Deakin University, Geelong, Victoria, Australia.
  • Barwon Health, Geelong, Victoria, Australia.
  • Box Hill Hospital, Eastern Health, Melbourne, Victoria, Australia.
  • The University of Auckland, Auckland, New Zealand.
  • Starship Children's Hospital, Te Whatu Ora-Health New Zealand Te Toka Tumai, Auckland, New Zealand.
  • Murdoch Children's Research Institute, Parkville, Victoria, Australia.

ORCID-Profile: Jessica C Costa-Pinto, Katherine J Lee, Lisa Gold, Peter D Sly, Peter Vuillermin

Förderung

  • National Health and Medical Research Council
  • Starship Foundation
  • Cure Kids
  • Auckland Medical Research Foundation
  • University of Auckland, PBRF Fund 2022 and 2023
  • Lottery Health Research
  • Health Research Council of New Zealand, Health Delivery Research
  • OM Pharma

Zitieren

APA

Costa-Pinto, J. C., van Arragon, M., Lee, K. J., Gold, L., Sly, P. D., Grant, C. C., McNab, S., Vuillermin, P., & Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) Investigator Group (2026). Assessing the Reduction of Recurrent Admissions Using OM ‐85 for the Treatment of Preschool Wheeze ( ARROW ): Protocol for a Multi‐Centre, Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Paediatrics and Child Health, 62(7), 1244-1254. https://doi.org/10.1111/jpc.70434

Vancouver

Costa-Pinto JC, van Arragon M, Lee KJ, Gold L, Sly PD, Grant CC, et al. Assessing the Reduction of Recurrent Admissions Using OM ‐85 for the Treatment of Preschool Wheeze ( ARROW ): Protocol for a Multi‐Centre, Randomised, Double‐Blind, Placebo‐Controlled Trial. Journal of Paediatrics and Child Health. 2026;62(7):1244-1254. doi:10.1111/jpc.70434

BibTeX
@article{CostaPinto2026,
  author = {Costa-Pinto, Jessica C and van Arragon, Marisa and Lee, Katherine J and Gold, Lisa and Sly, Peter D and Grant, Cameron C and McNab, Sarah and Vuillermin, Peter and Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) Investigator Group, Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) Investigator Group},
  title = {Assessing the Reduction of Recurrent Admissions Using OM ‐85 for the Treatment of Preschool Wheeze ( ARROW ): Protocol for a Multi‐Centre, Randomised, Double‐Blind, Placebo‐Controlled Trial},
  journal = {Journal of Paediatrics and Child Health},
  year = {2026},
  volume = {62},
  number = {7},
  pages = {1244--1254},
  doi = {10.1111/jpc.70434}
}
Kostenlos starten →